Seres Therapeutics, Inc. (MCRB)

Price$7.17

Value ScoreC

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-70.39%

Price vs S&P 500 (4W)-7.21%

VGM Score40.87

Market Capitalization$71.85M

P/E Ratio (Annual)12.62x

All Metrics

P/CF (Annual)64.33x

Book Value / Share (Quarterly)$2.76

P/TBV (Annual)13.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-71.62%

Cash Flow / Share (Quarterly)$-4.42

Price vs S&P 500 (YTD)-62.13%

Net Profit Margin (TTM)-2357.80%

EPS (TTM)$-5.08

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-5.08

Revenue Growth (5Y)-52.34%

EPS (Annual)$0.64

ROI (Annual)12.88%

Net Profit Margin (5Y Avg)-29.07%

Cash / Share (Quarterly)$3.11

P/E Basic Excl Extra (TTM)13.63x

P/E Normalized (Annual)12.62x

ROA (Last FY)4.12%

EBITD / Share (TTM)$-6.09

ROE (5Y Avg)-481.38%

Operating Margin (TTM)-3002.79%

Cash Flow / Share (Annual)$0.09

P/B Ratio2.71x

P/B Ratio (Quarterly)3.21x

Net Income / Employee (Annual)$86,300

EV / Revenue (TTM)36.64x

Net Interest Coverage (TTM)-60.98x

ROA (TTM)-34.54%

EPS Growth QoQ (YoY)60.81%

EV / EBITDA (TTM)6.16x

EPS Incl Extra (Annual)$0.64

Current Ratio (Annual)2.56x

Quick Ratio (Quarterly)1.55x

3-Month Avg Trading Volume0.06M

52-Week Price Return4.71%

EV / Free Cash Flow (Annual)48.58x

P/E Incl Extra (TTM)13.63x

Revenue / Employee (TTM)$17,400

Tangible BV / Share (Quarterly)$-0.12

P/S Ratio (Annual)91.07x

Asset Turnover (Annual)0.01x

52-Week High$29.98

Operating Margin (5Y Avg)-511.36%

EPS Excl Extra (Annual)$0.64

CapEx CAGR (5Y)-15.67%

Tangible BV CAGR (5Y)-29.22%

26-Week Price Return-56.81%

Quick Ratio (Annual)2.40x

13-Week Price Return-18.19%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.65x

Enterprise Value$42.02M

Revenue / Share Growth (5Y)-35.44%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)25.33%

Revenue / Employee (Annual)$12,000

Pretax Margin (Annual)721.93%

Cash / Share (Annual)$4.79

3-Month Return Std Dev58.18%

Net Income / Employee (TTM)$-710,600

ROE (Last FY)12.88%

Net Interest Coverage (Annual)-12.95x

EPS Basic Excl Extra (Annual)$0.64

P/FCF (TTM)2.47x

Receivables Turnover (TTM)30.88x

EV / Free Cash Flow (TTM)36.84x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.08

ROI (TTM)-127.30%

P/S Ratio (TTM)62.65x

Pretax Margin (5Y Avg)-29.07%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.09

Forward P/E33.91x

Price vs S&P 500 (52W)-23.44%

P/E Ratio (TTM)13.63x

Year-to-Date Return-50.74%

5-Day Price Return-3.93%

EPS Normalized (Annual)$0.64

ROA (5Y Avg)-23.54%

Net Profit Margin (Annual)721.93%

Month-to-Date Return0.14%

Cash Flow / Share (TTM)$-1.06

EBITD / Share (Annual)$-1.03

Operating Margin (Annual)-1683.90%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)69.50x

ROI (5Y Avg)-95.46%

P/E Excl Extra (TTM)13.63x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.08

P/B Ratio (Annual)3.04x

Pretax Margin (TTM)-2357.80%

Book Value / Share (Annual)$4.63

Price vs S&P 500 (13W)-28.86%

Beta0.18x

P/FCF (Annual)83.07x

Revenue / Share (TTM)$0.12

ROE (TTM)-127.30%

52-Week Low$6.56

vGradeC

gGradeD

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-2.08est. -1.92

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.89

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MCRBSeres Therapeutics, Inc.	C	D	D	$7.17
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Seres Therapeutics is a microbiome therapeutics company developing biological drugs designed to restore and repair the function of dysbiotic microbiomes. The company's lead product, SER-109, is designed to prevent recurrent Clostridium difficile infection (CDI), a serious colon infection. The company is also advancing a pipeline of additional candidates including SER-262, SER-287, and SER-401.